双胎妊娠无创产前筛查:IONA检测的前瞻性多中心研究
该前瞻性多中心盲法研究在6个英国胎儿医学中心招募1003例双胎妊娠,评估游离DNA(IONA检测)筛查常见三体的性能。961例有完整数据,失败率0.31%。21三体检出率100%(n=13),18三体0%(n=1),13三体100%(n=1);合并11项研究后21三体检出率95%,假阳性率0.09%。结论认为游离DNA是双胎21三体最准确筛查方法。
要点
- 双胎妊娠游离DNA筛查失败率低(0.31%),21三体检出率100%(n=13)。
- 18三体检出率0%(n=1),13三体100%(n=1),但病例数极少。
- 合并分析显示双胎21三体检出率95%,假阳性率0.09%。
核心结论
- 游离DNA是双胎妊娠21三体最准确的筛查方法,性能与单胎相似且失败率低。
- 对18和13三体的预测准确性可能较低,但假阳性率低,可考虑作为双胎21三体的一线筛查。
研究设计与样本
- 前瞻性多中心盲法研究,在英国6个胎儿医学中心招募1003例双胎妊娠,961例有完整随访和参考数据。
- 采用下一代测序的IONA检测,并按照STARD标准报告,同时合并文献检索(截至2020年6月6日)的11项研究进行汇总分析。
主要发现
- 失败率0.31%,平均胎儿分数12.2%(范围3%-36%),9例胎儿分数3%的样本均获得有效结果。
- 21三体无假阳性或假阴性,检出率100%(n=13;95%CI 75-100),假阳性率0%(95%CI 0-0.39)。
- 18三体1例假阴性和1例假阳性,检出率0%(n=1;95%CI 0-98),假阳性率0.10%(95%CI 0-0.58)。
- 13三体检出率100%(n=1;95%CI 3-100),假阳性率0%(95%CI 0-0.39)。
- 合并分析:21三体检出率95%(n=74;95%CI 90-99),假阳性率0.09%(n=5598;95%CI 0.03-0.19);18三体检出率82%(n=22;95%CI 66-93),假阳性率0.08%(n=4869;95%CI 0.02-0.18);13三体平均检出率80%,假阳性率0.13%(5例病例,3881例非13三体)。
临床怎么用
- 对于双胎妊娠,可考虑将游离DNA作为21三体的一线筛查选项,尤其因其低失败率和低假阳性率。
- 筛查18和13三体时需注意准确性可能较低,阳性结果应通过诊断性检测确认。
局限性
- 18和13三体的病例数极少(分别为1例和1例),导致检出率估计不稳定。
- 研究仅在英国6个中心进行,外部推广性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In singleton pregnancies, studies investigating cell-free DNA in maternal blood have consistently reported high detection rate and low false-positive rate for the 3 common fetal trisomies (trisomies 21, 18, and 13). The potential advantages of noninvasive prenatal testing in twin pregnancies are even greater than in singletons, in particular lower need for invasive testing and consequent fetal loss rate. However, several organizations do not recommend cell-free DNA in twin pregnancies and call for larger prospective studies. OBJECTIVE: In response to this, we undertook a large prospective multicenter study to establish the screening performance of cell-free DNA for the 3 common trisomies in twin pregnancies. Moreover, we combined our data with that reported in published studies to obtain the best estimate of screening performance. STUDY DESIGN: This was a prospective multicenter blinded study evaluating the screening performance of cell-free DNA in maternal plasma for the detection of fetal trisomies in twin pregnancies. The study took place in 6 fetal medicine centers in England, United Kingdom. The primary outcome was the screening performance and test failure rate of cell-free DNA using next generation sequencing (the IONA test). Maternal blood was taken at the time of (or after) a conventional screening test. Data were collected at enrolment, at any relevant invasive testing throughout pregnancy, and after delivery until the time of hospital discharge. Prospective detailed outcome ascertainment was undertaken on all newborns. The study was undertaken and reported according to the Standards for Reporting of Diagnostic Accuracy Studies. A pooled analysis was also undertaken using our data and those in the studies identified by a literature search (MEDLINE, Embase, CENTRAL, Cochrane Library, and ClinicalTrials.gov) on June 6, 2020. RESULTS: A total of 1003 women with twin pregnancies were recruited, and complete data with follow-up and reference data were available for 961 (95.8%); 276 were monochorionic and 685 were dichorionic. The failure rate was 0.31%. The mean fetal fraction was 12.2% (range, 3%-36%); all 9 samples with a 3% fetal fraction provided a valid result. There were no false-positive or false-negative results for trisomy 21 or trisomy 13, whereas there was 1 false-negative and 1 false-positive result for trisomy 18. The IONA test had a detection rate of 100% for trisomy 21 (n=13; 95% confidence interval, 75-100), 0% for trisomy 18 (n=1; 95% confidence interval, 0-98), and 100% for trisomy 13 (n=1; 95% confidence interval, 3-100). The corresponding false-positive rates were 0% (95% confidence interval, 0-0.39), 0.10% (95% confidence interval, 0-0.58), and 0% (95% confidence interval, 0-0.39), respectively. By combining data from our study with the 11 studies identified by literature search, the detection rate for trisomy 21 was 95% (n=74; 95% confidence interval, 90-99) and the false-positive rate was 0.09% (n=5598; 95% confidence interval, 0.03-0.19). The corresponding values for trisomy 18 were 82% (n=22; 95% confidence interval, 66-93) and 0.08% (n=4869; 95% confidence interval, 0.02-0.18), respectively. There were 5 cases of trisomy 13 and 3881 non-trisomy 13 pregnancies, resulting in a computed average detection rate of 80% and a false-positive rate of 0.13%. CONCLUSION: This large multicenter study confirms that cell-free DNA testing is the most accurate screening test for trisomy 21 in twin pregnancies, with screening performance similar to that in singletons and very low failure rates (0.31%). The predictive accuracy for trisomies 18 and 13 may be less. However, given the low false-positive rate, offering first-line screening with cell-free DNA to women with twin pregnancy is appropriate in our view and should be considered a primary screening test for trisomy 21 in twins.
引用
- Khalil A, Archer R, Hutchinson V, et al. Noninvasive prenatal screening in twin pregnancies with cell-free DNA using the IONA test: a prospective multicenter study. Am J Obstet Gynecol. 2021. PMID: 33460583. doi:10.1016/j.ajog.2021.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。